Friday 16 October 2026
Export TLSA’s income statement to Excel — free account
Tiziana Life Sciences Ltd
TLSA Healthcare Biotechnology
Insiders bought in the last twelve months.
1.06
0.01
+0.95%
Follow TLSA
| Older periods | Jun '24 | Dec '24 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.85 | 1.02 | 1.72 | 0.76 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.23) | (0.15) | (0.07) | (0.09) | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | — | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
0.39 | (1.54) | (6.83) | (12.87) | |
Working Capital |
(1.32) | 0.16 | 5.32 | (2.66) | |
Capital Expenditures |
(0.01) | (0.02) | (0.01) | (0.02) | |
Net Current Asset Value |
(1.36) | 0.16 | 5.32 | (2.89) | |
| Other line items | |||||
Quick Ratio |
0.82 | 1.00 | 1.65 | 0.72 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
5.58 | 4.75 | 6.42 | 5.01 | |
Average Payables |
7.10 | 6.88 | 5.47 | 8.42 | |
Average Assets |
23.04 | 18.88 | 17.01 | 11.84 | |
Average Common Equity |
15.85 | 11.75 | 11.25 | 2.79 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates